Human Albumin Baxalta (Human Serum Albumin)

Human Albumin Baxalta is employed in clinical settings where plasma volume expansion or albumin replacement is required.

• Treatment of hypovolemia associated with acute blood loss or dehydration.
• Management of shock, including septic or hemorrhagic shock.
• Support for patients with extensive burns to maintain intravascular volume.
• Correction of hypoalbuminemia in liver disease, nephrotic syndrome, or chronic malnutrition.
• Adjunct therapy during renal dialysis when low albumin contributes to fluid shifts.
• Perioperative volume management in major surgery.

• Human Albumin Baxalta works by increasing the oncotic pressure of plasma. The infused human serum albumin molecules bind water within the vascular compartment, drawing fluid from the interstitial space back into the bloodstream. This rise in oncotic pressure expands intravascular volume, improves tissue perfusion, and helps maintain hemodynamic stability. The albumin also serves as a carrier for endogenous substances such as hormones, fatty acids, and drugs.

Adverse reactions to Human Albumin Baxalta are generally infrequent but can range from mild to severe.

Common

• Transient fever or chills.
• Mild hypotension or hypertension.
• Headache.
• Nausea or vomiting.
• Local irritation at the infusion site.

Serious

• Anaphylactic or severe allergic reactions.
• Acute hemolysis.
• Volume overload leading to pulmonary edema.
• Thromboembolic events.
• Renal dysfunction.

Clinicians should evaluate patient history and clinical status before administering Human Albumin Baxalta to minimize risk.

• Assess for known hypersensitivity to human albumin or any component of the solution.
• Use caution in patients with congestive heart failure or pulmonary edema due to risk of volume overload.
• Monitor fluid balance and electrolytes during and after infusion.
• Avoid rapid infusion rates that may provoke cardiovascular instability.
• Evaluate renal and hepatic function, as impairment may affect albumin metabolism.
• Consider the potential for increased intracranial pressure in patients with head trauma.

Human Albumin Baxalta may interact with other therapies that influence fluid balance, coagulation, or immune response.

Avoid

• Concurrent administration of other volume expanders (e.g., synthetic colloids) without careful monitoring.
• Use with drugs that have a high risk of anaphylaxis, such as certain antibiotics or contrast agents, without pre‑medication.

Use with caution

• Diuretics, which may exacerbate intravascular volume shifts.
• Vasopressors, as combined effects on blood pressure require close observation.
• Anticoagulants, because changes in plasma protein levels can alter drug binding.
• Immunosuppressants, due to potential modulation of immune reactions.